AGENT FOR EHRLICH TUMOUR INHIBITION

摘要

FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmacology and oncology, particularly to a new antitumour agent. Beta-ethyldiphacyl is presented to be used as an agent of an epithelial tumour (carcinoma) inhibition. There is provided to administer Ethyldiphacyl in doses of 15-50 mg/kg both before, and after the tumour grafting; the therapeutic course is up to 2 months after the tumour grafting with administrations following every 6-7 days; or preventive administration is performed 2-24 hours before the tumour grafting.EFFECT: technical effect consists in prolonging the life of mammals suffering the from the tumour by 30%; the life is not burdened with the disease progression.4 cl, 1 tbl